What is the mechanism of action of misoprostol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mechanism of Action of Misoprostol

Misoprostol is a synthetic prostaglandin E1 (PGE1) analog that exerts its therapeutic effects through binding to specific prostaglandin receptors, producing both antisecretory effects (inhibiting gastric acid secretion) and direct smooth muscle contractile effects, particularly on the uterus. 1

Molecular Mechanism

Receptor Binding and Cellular Action

  • Misoprostol binds to specific prostaglandin receptors on target cells with high affinity, demonstrating saturable, reversible, and stereospecific binding characteristics 1
  • These receptors show high affinity for misoprostol, its active acid metabolite, and other E-type prostaglandins, but not for F or I prostaglandins or unrelated compounds like histamine or cimetidine 1
  • The receptor-site affinity correlates directly with antisecretory activity 1

Active Metabolite Formation

  • After oral administration, misoprostol undergoes rapid de-esterification to misoprostol acid, which is the biologically active compound responsible for clinical effects 1
  • Peak plasma concentration (Tmax) of misoprostol acid occurs at 12 ± 3 minutes, with a terminal half-life of 20–40 minutes 1

Gastric Effects

Antisecretory Actions

  • Misoprostol inhibits basal, nocturnal, and stimulated gastric acid secretion through direct action on parietal cells 1
  • At doses of 200 mcg and above, it reduces basal acid secretion by 91–93% and pentagastrin-stimulated acid secretion by 27–51% depending on dose 2
  • Activity begins within 30 minutes of oral administration and persists for at least 3 hours 1

Mucosal Protective (Cytoprotective) Effects

  • Misoprostol increases gastric bicarbonate secretion, which neutralizes acid at the mucosal surface 1, 3
  • It stimulates mucus production, with increases of 37–95% during the basal period depending on dose 2
  • The concentration of gastric juice mucus is significantly increased, providing a protective barrier 2
  • These cytoprotective effects occur independently of antisecretory actions 3

Uterine Effects

Myometrial Contractility

  • Misoprostol produces direct uterine contractions that can expel pregnancy tissue 4, 1
  • It is classified as a PGE1 analog and is the most commonly studied prostaglandin for medication abortion 4
  • The drug elicits dose-dependent effects on myometrial contractility 5

Cervical Ripening

  • Misoprostol increases inflammatory mediators in the cervix, promoting cervical remodeling 5
  • It induces changes in the cervical extracellular matrix through inflammatory pathways 5

Clinical Pharmacology Considerations

Absorption and Distribution

  • Misoprostol is extensively absorbed after oral administration 1
  • Serum protein binding is less than 90% and is concentration-independent in the therapeutic range 1
  • Maximum plasma concentrations are diminished when taken with food, though this does not appear clinically significant 1

Metabolism and Excretion

  • The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction 1
  • Approximately 80% of radioactivity appears in urine after oral administration 1

Important Clinical Caveats

  • The mechanism differs from PGE2 (dinoprostone): while both induce cervical ripening, PGE2 specifically stimulates interleukin-8 and induces functional progesterone withdrawal, whereas misoprostol's primary advantage is its dose-dependent myometrial effect 5
  • Misoprostol does not affect hepatic cytochrome P-450 enzyme systems and has minimal drug interactions 1
  • The drug is stable at room temperature, unlike other prostaglandin analogs that require refrigeration 4

References

2
Research

Effects of misoprostol on gastric acid and mucus secretion in man.

Digestive diseases and sciences, 1986

Related Questions

Should I take an additional four tablets of misoprostol after experiencing heavy bleeding with clots following the initial dose?
Is a baseline electrocardiogram required before starting Korlym (mifepristone)?
What psychiatric side effects can occur with Korlym (mifepristone) and how should they be monitored and managed?
Can Korlym (mifepristone) cause burning or stinging sensations in the legs and shortness of breath?
What is the recommended interval between misoprostol and levothyroxine administration?
What is the recommended intramuscular dose and regimen of Solu‑Medrol (methylprednisolone sodium succinate) for an adult with an acute inflammatory rash?
What oral corticosteroid is preferred for treating a severe rash in an adult?
What is the appropriate management for a patient with total cholesterol 260 mg/dL, LDL (low-density lipoprotein) 179 mg/dL, HDL (high-density lipoprotein) 44 mg/dL, triglycerides 184 mg/dL, hemoglobin A1c (HbA1c) 5.1 % and fasting glucose 85 mg/dL?
Can solumedrol (methylprednisolone) be used to treat a full-body rash?
In a patient with total cholesterol 260 mg/dL, LDL‑C 179 mg/dL, HDL‑C 44 mg/dL, triglycerides 184 mg/dL, HbA1c 5.1 % and fasting glucose 85 mg/dL, can rosuvastatin 20 mg be initiated on an every‑other‑day schedule?
Is enoxaparin (Lovenox) required when an inferior vena cava (IVC) filter is placed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.